CA2574103A1

CA2574103A1 - Novel potent inducers of terminal differentiation and methods of use thereof

Info

Publication number: CA2574103A1
Application number: CA002574103A
Authority: CA
Inventors: Ronald Breslow; Paul A. Marks; Richard A. Rifkind
Original assignee: Individual
Current assignee: Columbia University in the City of New York; Memorial Sloan Kettering Cancer Center
Priority date: 1994-05-19
Filing date: 1995-05-19
Publication date: 1995-11-30

Abstract

The present invention provides the compound having structure (I), wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiazoleamino group; when R1 and R2 are different, R1 = R3-N-R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8. The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.

Description

wu 95/s1977 . Y(:17UJY'/VO"4 NOVEL POTENT INDUCERS OF TERMINAL
DIFFERENTIATION AND METHODS OF USE THEREOF
This application is a continuation~in-part of U.S. Serial No.
07/771,760, filed October 4, 1991, now issued as U.S. Patent No.
5,369,108. The invention described herein was made in the course of work under Grant Number CA-'S7227-O1 from the National institutes of Health. The United States Government has certain rights in this invention.
Background of the Invention Throughout this application various publications are referenced by arabic numerals within parentheses. Full citations for these publications may be found at the end of the .specification ,immediately preceding the claims.
The disc_~.osures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
Cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms which noimally govern proliferation and differentiation. For many years thE~~ have been two principal strategies for chemotherapeutic treatment of .cancer: .a) blocking hornnone-dependent tumor cell proliferation by interference with the production or peripheral action of sex hormones; and b) killing cancer cells directly by exposing them to cytotoxic substances, which injure both neoplastic and normal cell populations.
Relatively recently, cancer therapy is also being attempted by the induction of terminal differentiation of the neoplastic cells (1). In cell culture models differentiation has been reported by exposure of cells to WO 95131977 ~ ~ PCT/US95/06554 a variety of stimuli, including: cyclic AMP and retinoic acid (2,3), aclarubicin and other anthracyclines (4).
There is abundant evidence that neoplast?~ transformation does not necessarily destroy the potential of cancer cells to differentiate (1,5,F). There are many examples of tumor cells which do not respond to the normal regulators of proliferation and appear to be blocked in the expression of their differentiation program, and yet can be induced to differentiate and cease replicating.
A variety of agents, including some relatively simple polar compounds (5,7-9), derivatives of vitamin D and retinoic acid (10-12), steroid hormones (13), growth factors (6,14), proteases (15,16), tutor promoters (17,18), and inhibitors of DNA or RNA synthesis (4,19-24), can induce various transformed cell lines and primary human tumor explants to expres ~ more differentiated characteristics.
Early studies by the present inventors identified a series of polar compounds that were effective inducers of differentiation in a number of transformed cell lines (8,9). Of these, the most effective inducer, was the hybrid polar/apolar compound N,N~-hexamethylene bisacetamide (HI~A) (9). The use of this polar/apolar compound to induce murine erythroleukemia cells (MELC) to undergo erythroid differentiation with suppression of oncogenicity has proved a useful model to study inducer-mediated differentiation of transformed cells (5,7-9).
~A-induced MELC terminal erythroid differentiation is a multistep process. Upon addition of HI~A to MELC
(745A-DS19) in culture, there is a latent period of ZO to 1~ hours before commitment to terminal differentiation is detected. Commitment is defined as the capacity of cells to express terminal differentiation despite removal of inducer (25). Upon continued exposure to HI~A there is progressive recruitment of cells to differentiate. The WO 95131977 ~- PCT/OS95/06554 present inventors have reported that MELC cell lines made resistant to relatively low levels of vincristine become markedly more sensitive to the inducing action of HN~A
and can be induced to differentiate with little or no latent period (26).
HI~A is capable of inducing phenotypic changes consistent with differentiation in a broad variety of cells lines (5). The characteristics of the drug induced effect have been most extensively studied in the murine erythroleukemia cell system (MELC) (5,25,27,28). MELC
induction of differentiation is both time . and - concentration dependent. The minimum concentration required to demonstrate an effect ~n_ grit o in most strains is 2 to 3 mM; the minimum duration of continuous exposure generally required to induce differentiation in~
a substantial portion (~20%) of the population without - continuing drug exposure is about 36 hours., The primary target of action of HI~A is not known. There is evidence that protein kinase C is involved in the pathway of induces-mediated differentiation (29). The in vitro studies provided a basis for evaluating the potential of HI~A as a cytodifferentiation agent in the treatment of human cancers (30). Several phase i clinical trials with HI~A have been completed (31-36).
Clinical trials have shown that this compound can induce therapeutic response in patients with cancer (f5,36).
However, these phasa I clinical trials also have demonstrated that the potential efficaey of HI~A is limited, in Bart, by dose-related toxicity which prevents achieving optimal blood levels and by the need for intravenous administration of large quantities of the agent, over prolonged periods. -Recently, the present inventors have reported a number of compounds related to HI~3A with polar groups separated by apolar linkages that, on~a molar basis, are as active (37) or 100 times more active than HI~A (38) . As a class, however, it has been found that the symmetrical dimers such as HI~A and related compounds are not the best cytodifferentiating agents.
It has unexpectedly been found that the best compounds comprise two polar end groups separated by a flexible chain of methylene groups, wherein one or both of the polar end groups is a large hydrophobic group.
Preferably, the polar end groups are different and only one is a large hydrophobic group. These compounds are unexpectedly a thousand times more active than HI~A and ten times more active than HI~A related co3npounds.
This new class of compounds of the present invention may be useful for selectively inducing terminal differentiation of neoplastic cells and therefore aid in treatment of tumors in patients.

~WO 95131977 PCT/US95/06554 Summary of the Invention The present invention provides the compound having the structure:
O
R1 ~
C ---( C H 2 n3~-- \
herein each of RI and RZ are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidiri~, 9-purine-6-amine, or thiazoleamino group; when R1 and R2 are different, R1 - R3-N-R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together . to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
The present invention also provides the compound above having the structure:
~R4 G
R3 N\
C-'t GH
2 n \

wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted ~or unsubstituted, branched 'WO 95/31977 PCTIUS95106554 or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group; RZ is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
The present invention also provides the compound above having the structure:
R\
C ----( G H ~
2 n \
~ R w wherein R is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiazoleamino group; and n is an integer from about 4 ~o about e.
The present invention also provides the compound having the structure:

G-'-( Cg ~--C N C CH
Y
R
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylainino, or aryloxyalkylamino group; R is a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group;
and each of m and n are independently the same as or 7 .. ' PGT/US95/06554 different from each other and are each an integer from about 0 to about 8.
The present invention further provides the compound having the structure:
;, II II ' C ( CH2 -~ 0- ~ (0g2 ~ i -C- ( CHI )o C
% ~Y
X
8i R2 wherein each of X and Y are independently the same as or .. different from each other and are a hydroxyl,. amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, ~ arylamino, alkylarylamino, alkyloxyamino, aryloxyamino;
alkyloxyalkylamino, or aryloxyalkylamino group; each of R, and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m, n, and o are independently the same as or different from each other and are each an integer from about 0 to about 8.
The present invention still further provides the compound having the structure:
~~ II II ii X,c ccaz ~, i c ~c- i -tca2;~c~Y

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino .group; a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, _g_ alkyloxyalkylamino, or aryloxyalkylamino group; each of R, and Rz are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
The present invention also provides the compound having the structure:
°w ~~ II II
c- c c$2 ~-c-~rx-c ~c-NH-c- t cHZ ~-c ~Y
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and each of m and n are independently the same as or different from each other and are each an integer~from about 0 to about 8.
The present invention also provides the compound having the structure:

//
O~C.-- (CH C-N1 ~ ~ Nz C (CH C
x~ 2~ ~~ (~ Z~ ~Y

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamir~o, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, WO 95131977 PGT/U593/06554 .
_g_ alkyloxyalkylamino, or aryloxyalkylamino group; each of R, and R: are independently the same as or different from each ot=r and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
The present. invention further provides the compound having the structure:
CH3 . ~g~
I I /j c c ~cx" ~
g/ I ~ I Y
H , h wherein each of X and Y are independently the same as or dif f erent from each other and are a- hydroxyl , amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, 2.0 alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamirio group; and n is an integer from about 0 to about 8.
The present invention still further provides the compound having the structure.:
\\ ( s /%
/C ~CHZ ~ C (CH2 k1 I Y

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino; aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R, and R~ are independently the same as c~r different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, aryloxy, carbonylhydroxylamino, or fluoro group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
The present invention also provides the compound having the structure:
//
C C
J

wherein each of R~ and R2 are independently the same as or different from each other and are a hydroxyl, alkylbxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
The present invention also provides the compound having the structure:
R 1 ~~
~C GH CH CH . CH C~
. R2 wherein each of R, and RZ are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
The present invention further provides the compound WO 95!31977 -~ ~ PCT/LIS95I06554 , having the structure:

R1~
C ~ C~: CH C \
. ~ . R2 wherein each of R,~and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
The present invention further provides the compound having the structure: ~

_, ~ C~ R2 Rs _ C \
wherein each of R, a'nd RZ are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino;
arylamino, alkylarylami~na, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
The present invention further provides the compound having the structure:

3=CH-C-R2 ~~
3s . Rs-C

WO 95!31977 PCT/US95/06554 wherein each of R, and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
The present invention further provides the compound having the structure:

CH=CH-C-RZ

II
R1 C-CH=CH
wherein each of R1 and Rz are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
The present invention alSO provides the pharmaceutically acceptable salts of any of the compounds defined above.
The present invention further provides a compound having the structure:

R-C-N- (CHZ) n -C-NH-OH
I
H
wherein R is a substituted or unsubstituted phenyl, piperidine or thiazole. group and n is an integer from about 4 to about 8 or a pharmaceutically acceptable salt thereof .

WO 95131977 . ~ PCT/L1S95/06554 The present invention also provides a compound having the structure:
O O
R-C-N- (CHy) n -C-NH-OH
H
wherein R is a substituted or unsubstitued 2-pyridine, 3-pyridine, or 4-pyridine and n is an integer from about 4 to about 8 or a pharmaceutically acceptable salt thereof.
The present invention further provides a compound having the structure:

R_~_C_N_ (CHZ)n -C-1~I~.pH
H

wherein R is a substituted or unsubstituted phenyl, pyridine, piperidine or thiazole group and n is an . integer from about 4 to about 8 or a pharmaceutically acceptable salt thereof.
In addition, the present invention provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective .amount~of. any of the compounds above, effective to sE~ectively induce terminal differentiation.
The present invention also provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.

WO 95/31977 PCTlUS95/06554 The present invention also provides a pharmaceutical composition comprising a therapeutically acceptable amount of any of . the compounds above, or oharn~aceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
Lastly, the present invention provides the pharmaceutical composition defined above, alone or in combination with, an antitumor agent, in sustained rel-ease form.

WO 95/31977 PGT/US95/06554 .

Detailed Description of the Invention The present invention provides the compound having the structure:
. //C (CH2.~C~
R
IO wherein each of R, and RZ are independently the same as or different from each other; when R, and RZ are the same, each is a substituted or unsubstituted arylamino, cycloalkyl-amino, pyridineamino, piperidino, 9-purine-6-amine, or thiazoleamino group; when R, and R, are different, R, - R~-N-R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen.atom, a hydroxyl group, a substituted . or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridino group, or R3 and R4 bond together to form a piperidine group .and RZ is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
The present. invention also provides the compound above having the structure:
g4 R3 N~ 0 ~l ~0 ~CHZ~C~

wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom,-a _ hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy;
aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group; R= is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
In the preferred embodiment of the compound above, R~ is a hydroxylamino, hydroxyl, amino, methylamino, dimethylamino, or methyoxy group and n is 6. Most preferably, R4 is a hydrogen atom and R3 is a substituted or unsubstituted phenyl group.
The phenyl group may be substituted with a methyl, cyano, vitro, trifluoromethyl, amino, aminocarbonyl, methylcyano, chloro, fluoro, bromo, iodo,~i2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2,3-trifluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl, phenyl, carboxyl, hydroxyl, methyoxy, benzyloxy, phenylaminooxy, phenylmethoxy, phenylamino-carbonyl, methyoxycarbonyl, methylaminocarbonyl, dimethylamino, dimethylaminocarbonyl, or hydroxylamino-carbonyl group.
In other preferred embodiments of the compound above, R4 is a hydrogen atom and R3 is a cyclohexyl group; R, is a hydrogen atom and R3 is a methyoxy group; R3 and R4 each bond together to form a piperidine .group; R4 is a hydrogen atom and R3 is a hydroxyl group; R4 is a hydrogen atom and R3 is a benzyloxy group; R4 is a hydrogen atom and R3 is a b-pyridine group; R4 is a hydrogen atom and R3 is a i3-pyridine group; R4 is a hydrogen atom and R3 is a a-pyridine group; R3 and R4 are both methyl groups; or R, is a methyl group and R3 is a phenyl group.

WO 95131977 ~ PCT/US95/06554 The present invention also provides the compound having the structure:

\

wherein R is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiazoleamino group; and n is an integer from about 4 to about 8.

In the preferred embodiment of the compound above, R is a substituted-or unsubstituted phenylamino group. The phenylamino group may be substituted with a cyano, . methylcyano, nitro, carboxyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, trifluoromethyl, hydroxylamin.ocarbonyl, N-hydroxylaminocarbonyl, methoxycarbonyl, ctrloro, fluoro, methyl, methoxy, 2,3-difluoro, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 2,6~-difluoro, 3,~-difluoro, 2,6-difluoro, 2,3,6-trifluoro, 1,2,3-trifluoro, 3,4,5-trifluoro, 2,3,4,5-tetrafluoro, or 2,3,4;5,6-pentafluoro group.
.In another embodiment of the compound.above, R is a cyclohexylamino group.
The present invention also provides the compound having the structure:

.35 . C L CH ~--C N C.--( CH
X~ Z m ~ ( Y
g WO 95/31977 ' ~ PCT/L1S95/06554 wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyam.ino, alkyloxyalkylamino, or aryloxyalkylamino group; R is a hydrogen atom, a .hydroxyl group, a substituted or unsubsti.tuted alkyl, aryl, alkyloxy, or aryloxy group;
and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
In the preferred embodiment of the compound above, each of X, Y, and R is a hydroxyl group and each~of m and n is 5.
The present invention also provides the compound having the structure:
o\ II ~~ ____ I~
~c tcHZ m c- l ~c$2 ~ l -c t cg2 o c R1. g2 wherein each.of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, aikylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R~ and RZ are independently the same as or different from each other and are a hydrogen atom, a.hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each oi: m, n, and o are independently the same as or different from each other and are each an integer from about 0 to about 8.

WO 95/31977 ~ PCT/LTS95/06554 In the preferred embodiment of the compound above, each of X an~i Y is a hydroxyl group and each of R, and RZ is a methyl group. Most preferably, each of n and o is 6, and m is 2.
The present invention also provides the compound having the structure oy II II to (CH2 ) N-C y-C N L CH
.. i m .. I ~ I 2~ \
g ~ Y
Hi R2 wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R, and Rz are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about O to about 8.
The present invention also provides the compound having the structure:
II II (I fl ~I
~c- ccH2 ~m c-xH-c c-xa- c-tcaz~-c\
x wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
In the preferred embodiment of the compound above, each of X and~Y is a hydroxyl group and each of m and n is 5.
The present invention also provides the compound having the structure:
I1 IZ. II
C (CHZ ) C-N N-C (C$2 ) C
~~ n II II

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted _ 2S alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyami.no, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylannino group; each of R1 and R., are independently the same as or different f rom each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, .alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

WO 95/31977 PCT/US95/06554 .

The present invention also provides the compound having the structure:
0 _i H3 ~ g3 C C tCH2 )n X/ ~
H H
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or ~hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyl.oxyamino, aryloxyamin8, alkyloxyalkylamino, or aryloxyalkylamino group; and n is an integer from about 0 to about 8.
In the preferred embodiment of the compound above,, each of X and Y is a dimethylamino group and n is 4 or 5.
The present invention also provides the compound having the structure:
0 ' R1 ~ 0 . ~ I i . ./0 ~Cg2'~ 0 .(CH2 ~C\
I y wherein each of X and Y are independent3y the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, ' alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R, and RZ are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, i aryloxy, carbonylhydroxylamino, or fluoro group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
In the preferred embodiment of the compound above, each of X and Y is a hydroxylamino group, R1 is a methyl group, R2 is a hydrogen atom, and each of m and n is 2. In another preferred embodiment, each of X and Y is a hydroxylamino group, R, is a carbonylhydroxylamino group, R, is a hydrogen atom, and each of m and n is 5. In a further preferred embodiment, each of X and Y is a hydroxylamino group, each of R, and Rz is a fluoro group, and each of m and n is 2. ~
The present invention also provides the compound having!
the Structure:
// _ C C
~2 . R2 wherein each of R, and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino,. dialkylamino, arylarnim,~ alkylarylamino, alkyloxyamino, arylo3cyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
Preferably, R, is a phenylamino group and RZ is a hydroxylamino group.

WO 95!31977 PGT/US95106554 The present invention also provides the compound having the structure:
.R 1 \. . %0 .
C CH CH CH CH C
//

wherein each of R, and R, are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, - arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
Preferably, R1 is phenylamino group and RZ is hydroxylamino group:
The present invention also provides the compound having the structure:
R1\ ' /0 . /~ CH CH C~

wherein each of R, and Rz are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino;
alkyloxyalkylamino, or aryloxyalkylamino group.
In the preferred embodiment, either R, or RZ is ~ a hydroxylamino group.
The present invention also provides the compound having the structure:

~2 R1-C . , wherein each of R, and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino g''roup.
Tn a preferred embodiment; the compound above has the structure:

i1 p C-NH-OH
..
HO-NH-C
The present invention also provides a compound having the structure:
~i= C H- C - RZ

W0 95131977 . PGT/US95106554 wherein each of R, and R= are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino;
alkyloxyalkylamino~, or aryloxyalkylamino group.
In a preferred embodiment, the compound above has the structure:
~~
~ CH=CH-C-NH-OH
HO-NH-C
The present invention also provides a compound having the structure:
~~
CH= CH" C"- R2 Ii _ ~1 C- CH= C H
wherein each of R, and RZ are independently the same as or di f f event ~f rom each other and are a hydroxyl , a~kyloxy , amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
In the preferred embodiment , the compound def fined above has the structure:

WO 95/31977 PC'T/US95/06554 ~G
CH=CH-~~-NH-GH
0 ;
II
HG-NH-C-CH='Cii ~/ ~) -_%
The present invention also provides the pharmaceutically acceptable salts of any of the compounds defined above.
The present invention further provides a compound having the structure:

Il II
R-C-N- (CH2) o -C-NFi-OH
H
wherein R is a substituted or unsubstituted phenyl, piperidine or ehiazole group and n is an integer from about 4 to about 8 or a phazmaceutically acceptable salt thereof.
In .a pref erred embodiment of the .compound def fined above R is a substituted phenyl group. In a more preferred embodiment the phenyl group is substituted with a methyl, cyano, nitro, thio, trifluoromethyl, amino, aminocarbonyl, methylcyano, chloro, fluoro, bromo, iodo, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2,3-trifluoro, 2,3;6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl., phenyl, carboxyl, hydroxyl, methyoxy, phenyloxy, benzyloxy, phenylaminooxy, phenylaminocarbonyl, methyoxycarbonyl, methylaminocarbonyl, dimethylamino, dimethylamino-carbonyl, or hydroxylaminocarbonyl group.

The present invention also provides a compound having the structure:

R-C-N- (CHZ) p -C-NH-OH
H
wherein R is a substituted or unsubstitued 2-pyridine, 3-pyridine, or 4-pyridine and n is an integer from about 4 to about 8 or a pharmaceutically acceptable salt thereof .
The present invention further provides a compound having the structure:

~~ ~~
R=NH-C-N-(CHZ)Q -C-NH-OH
H
wherein R is a substituted or unsubstituted phenyl, pyridine, piperidine or thi.azole group and n is an integer from about 4 to about 8 or a pharmaceutically acceptable salt thereof.
In a preferred embodiment of the compound defined above, R is a substituted phenyl group. In a more preferred embodiment, the phenyl group is substituted with a methyl, cyano, vitro, thio, trifluoromethyl, amino, aminocarbonyl, methylcyano, chloro, fluoro, bromo,.iodo, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2;3-trifluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro; 2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl, phenyl, carboxyl, hydroxyl, methyoxy, phenyloxy, benzyloxy, phenylam'inooxy, phenylaminocarbonyl_, methyoxycarbonyl, methylarninocarbonyl, dimethylamino, dimethylamino-carbonyl, or hydroxylaminocarbonyl group.
In a further preferred embodiment the compound defined WO 95/319?? PCTlUS95/06554 above has the structure:

i-NH- (CH,) 5 -C-NH-OH
O
or a pharmaceutically acceptable salt thereof.
In a further preferred embodiment the compound defined above has the structure:
_ ~ ~ -N-H 0 Cl '- \4 -NH- (CHZ)s _~_~_Og y or a pharmaceutically acceptable salt thereof.
The present invention further provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting~the cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation.
The contacting must be performed continuously for a prolonged period of time, i.e. for at least 48 hours, preferably~for about 4-5 days or longer.
The method may be practiced i~ vivo or ~ vi ro. If the method is practiced 'fin vitro, contacting may be effected by incubating the cells with the compound. The concentration of the compound in contact with the cells should be from about T EcM to about 25 mM, preferably from 4 ~.cM to about 5 mM. The concentration, depends upon the individual compound and the state of the neoplastic cells.

a WO 95!31977 FCT/US95l06554 The method may also comprise initially treating the veils with an antitumor agent so as to~render them resistant to an antitumor agent and subsequently contacting the resulting resistant cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such cells. .
The antitumor agent may be one of numerous chemotherapy agents such as.an alkylating agent, an antimetaboiite, a hormonal agent, an antibiotic, colchicine, a vinca alkaloid, L-asparaginase, procarbazine, hydroxyurea, mitotane, nitrosoureas or an imidazole carboxamide.
Suitable agents are 'those agents which promote depolarization of tubulin. preferably the antitumor agent is colchicine or a vinca alkaloid; especially preferred are vinblastine and vincristine. In embodiments where the antitumor agent is vincristine, the cells preferably are treated so that they are resistant to vincristine at a concentration of about 5 mg/ml. The treating of the cells to render them resistant to an antitumor agent may be effected by Contacting the cells with the agent for a period of at least 3-5 days. The contacting of the resulting cells with any of the compounds above is performed as described previously.
The present invention also provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an effective amount of any of the compounds above, or pharmaceutically acceptable salts thereof, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
The method of the present invention is intended for the treatment of human patients with tumors. However, it is WO 95/31977 ~ ~ PCT/US95/06554 also likely that the method would be effective in the treatment of tumors in other mammals. '.'he term t~.:mor is intended to include any cancer :.aused by the proliferation of neoplastic cells, such as lung cancer, acute lymphoid myeloma, bladder melanoma, renal carcinoma, breast carcinoma, or colorectal carcinoma.
The administration of the compound to the patient may be effected orally or parenterally. To date, administration intravenously has proven to be effective. The administration of the compound must be performed continuously for a prolonged period of time, such as for at least 3 days and preferably more than 5 days. In the most preferred embodiments, the administration is effected continuously for at least 10~ days and is repeated at intervals wherein at each interval the administration is continuously effected for a,t .least 10 days. For example, the administration may be effected at intervals as short as 5-10 days, up to about 25-35 days and continuously for at least 10 days during each such interval. The optimal interval period will vary depending on the type of patient and tumor. For example, in the incidence of acute leukemia, the so called myelodysplastic syndrome, continuous infusion would seem to be indicated so long as the patient tolerated the drug without toxicity and there was a positive response.
The amount of the compound administered to the patient is less than an amount which would cause toxicity in the patient. In the certain embodiments, the amount of the compound which is administered to the patient is less than the amount Which causes a concentration of the compound in the patient's plasma to egual or exceed the toxic level of the compound. Preferably, the concentration of the compound in the patient's plasma is maintained at about 1.0 mM. It has been found with HI~A
that administration of the compound in an amount from about 5 gm/m2/day to about 30 gm/mi/day, particularly WO 95/31977 ~ PCT/US95106554 -3i-about 20 gm/m=/day, is effective without producing toxicity in the patient. The optimal amount of the compound which should be administered to the patient i:.
the..practice of the present invention will depend on the particular compound used and the type of cancer being treated.
This invention, in addition to the above listed compounds, is intended to encompass the use of homologs and analogs of such compounds. In this context, homologs are molecules having substantial structural similarities to the above-described compounds and analogs are molecules having substantial biological similarities regardless of structural similarities.
The method may also comprise initially administering to the patient an amount of an antitumor agent to render the cells resistant to an antitumor agent and subsequently administering to the patient an effective amount of any of the compounds above, or pharmaceutically acceptable salts thereof,~effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
The antitumor agent may be one of numerous chemotherapy agents such as an alkylating agent, an antimetabolite, a .. hormonal agent, an antibiotic, colchicine, a vinca alkaloid, L-asparaginase, procarbazine, hydroxyurea, "- mitotane, ni:trosoureas or an imidazole carboxamide.
Suitable agents are those agents which promote depolarization of tubulin. Preferably the antitumor agent is colchicine or a vinca alkaloid; especially preferred are vinblastine and vincristine. In embodiments where the antitumor agent is vincristine, an 35~~ amount is administered to render the cells are resistant to vincristine at a concentration of about 'S mg/ml. The administration of the agent is performed essentially as described above for the administration of any of the compounds. Preferably, the administration of the agent is for a period of at least 3-5 days. The admiristraticn of any of the compounds above is performed as descr ibed previously.
The present invention also provides a pharmaceutical composition comprising a therapeutically acceptable amount of~any of the compounds above, or pharmaceutically 3.0 acceptable salts thereof, and a pharmaceutically acceptable carrier, such as sterile pyrogen-free water.
preferably, the therapeutically acceptable amount is an amount effective to selectively induce terminal differentiation of suitable neoplastic ells and less than an amount which causes toxicity in a patient.
The present invention provides the pharmaceutical composition above in combination with an antitumor agent.
The antitumor agent may be any of the agents previously described.
Lastly, the present invention provides the pharmaceutical composition above, alone or in combination with an antitumor agent, in sustained release form. By "sustained release form" applicants mean incorporation of the pharmaceutical compositions in a pharmaceutically acceptable formulation which provides for the sustained release of a therapeutically effective amount of the compounds of this invention over a period of time necessary to derive the intended therapeutic effect.
Sustained release formulations of pharmaceutical compositions allow for less frequent administration of the compound and provide for administration of the pharmaceutical composition at or near the target area in a subject's system. Sustained release formulations and methods of incorporating pharmaceutical compositions therein are well known to those of ordinary skill in the art. Examples include, but are not limited to, suc:~
formulations as incorporation into ion exchange resins cU.S. Patent No. 5,296,228 to Chang et al.), xanthan gums (U. S. Patent No. 5,292,534 to Valentine at al.;, mic=ospheres (U.S. Patent No. 5,288,502 to McGinity et al.)~ hydrogels (U.S~. Patent No. 5;266,325 to Kuzma et al.) and solid forms such as wax-like or fat-like hydrophobic substances containing water insoluble polymers'(U.S. patent No. 5,270,055 to Moest). Methods of administering compounds for sustained-release are also known in the art and include, but are not limited to, surgical implantation of microencapsulated pharmaceutical compounds near the intended target site iU.S. Patent No.
- 5,290,271 to Jernberg) and incorporation of compound into transdertnal patches (U.S. Patent No. 5,298,256 to Flockhart et sal. and U.S. Patent No. 5,290,561 to Farhadieh et al.). The text of the above cited patents and the references disclosed therein are hereby encorporated by reference in their entirety into this disclosure.
The invention is. illustrated in the Experimental Details section which follows. This section is set Earth to aid in an understandirig of the invention but is not intended 0, and should not be construed to, limit in any way the ' invention as aet. forth in the claims which follow thereafter.

WO 95131977 ~ PCTlUS95106554 Experimental Details Cells and Materials MELC 745A-DS19 cells and the variants of MELC derived from this cell line, namely, the vincristine-resistant MELC V3.17 and VCR.C(2)15 cell lines (26i, and the dimethylsulfoxide-resistant cell line, DR10 (39), were maintained in alpha minimal essential medium containing 10% fetal calf serum (16). Cell cultures for all experiments were initiated with cells in logarithmic growth phase (day 2 cultured cells) at a density of 105 cells/ml. Inducer compounds were added in the final concentrations indicated below, dissolved in culture medium without fetal calf serum unless otherwise indicated. Cell density and benzidine reactively were determined as described (16).
Commitment to terminal differentiation, characterized by limited cell division (colony size <32 cells) and accumulation of hemoglobin (benzidine reactive colonies) was assayed by a colony cloning assay using 2%
methylcellulose as described (25) (see Table I for results). . -HL-60 human leukemia cells, derived from peripheral blood leukocytes of a patient with acute promyelocytic leukemia (40). Induced differentiation of HL-50~cells assayed by deterniining the proportion of cells that developed the capacity to reduce nitroblue tetrazolium (NBT) (41) (see Table 2 for results).

WO 95/31977 ' PCT/US95/06554 Chemistrv The compounds having the structure:
C.

R~ vfi-. , ~~
- NHGI
Preparation of PhCH.ONHOCtCH,)bC00CH3:
A solution of suberic acid monomethyl ester (1.9 g; 0.01 mol), oxaloyl chloride (1.75 mL; 2.54 g; 0.02 mol) and 0.1 mL DMF in benzene (200 mL) was stirred overnight at room temperature. The solvent was evaporated and oily residue was dissolved in chloroform (--20 mL) and mixed together with ,chloroform so3ution (100 mL) of, 0-benzylhydroxylamine (2.46 g; 0.02 mol) and pyridine (1.6 mL; 1.68 g; 0.02 mol). The reaction mixture was stirred at room temperature overnight. The chloroform solution was washed with water (50 mL), 10% hydrochloric acid, and again with water (2 x 50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated.
The solid residue was slurried in hexanes (--100 mL) and filtered. The yield of PhCH20NIi0C (CH2) bC00CH3 was 2 : 61 g (89%).
o\
\C (CH2 ?-C
OHN/ 6 \4CH3 The above suberic acid monobenzyloxyamide monomethyl ester (l g; 3.4 mol) was dissolved in dry methanol (50 WO 95/31977 ' PGTlUS95/06554 mL) and S% Pd-C ;50 mg) was added. Tfe black suspensio:
was shaken under hydrogen pressure (--50 psi) overnight at room temperature. The catalyst was separated by =i!tratior_, and filtrate .was evaporated. The soli~3 residue was slurried ir_ hexanes ~:~20 mL) and filtered.
The yield of the monomethyl ester monohydroxamic acid of suberic acid was 900 mg (95%).
~ H NNl~t ( DMSO - d6 , 2 0 0 Ngiz ) , b ( ppm ) 10 . 31 ( s , NHOH , 1 H ) ;

8.89 (s, broad, NHOH, 1H); 3.57 (s, CH3, 3H); 2.27 (t, J=7.4Hz, CH:COOCH3, 2H); 1.91 (t, J=7.4Hz, CH=CONHOH, 2H);
1.49 (m, 4H) , 1.24 (m, 4H) .
a 1~ ~~ //
/~' (CH2 6 C\
HOHN OH
Suberic acid monobenzyloxyamide monomethyl ester (1g; 3.4 mmol) and potassium hydroxide (210 mg; 3.75.mmo1) were dissolved in 10 mL of methanol-water (4:1) mixture. The reaction mixture was refluxed two hours and solvent was evaporated. The solid residue was dissolved in 5 mL
water and acidified with cone, hydrochloric acid to pH--5.
White precipitate was filtered, dried and crystallized from ethyl acetate-hexanes. The yield of suberic acid monobenzyloxyamide was 820 mg (86%). The product was dissolved in methanol (50 mL) and 5% Pd-C (50 mg) was added. The reaction mixture was shaken under hydrogen pressure (50 psi) overnight. The catalyst was separated by filtration and filtrate was evaporated. The solid residue was slurried in hexanes and filtered. The yield of suberic acid monohydroxamic acid was 520 mg (81%). 'H
NMR (DMSO-d6, 200 NlEiz) , b (ppm) 11.96 (s, broad, COOH, 1H) ;
10.31 (s, NHOH, 1H); 8.63 (s, broad, NHOH, 1H); 2.17 (s, J=7.4Hz, CHZCOOH, 2H) ; 1.91 (s, CHZCONHOH, 2H) ; 1.46 (m, WO 95131977 PG'T/US95/06554 4H); 1.22 (m, 4H).
Compounds having the structure:
J
ri_, a t~ .~3~ ~-.\
I J ~ ?~i HO H
G
General Procedure A' pyridine (500 mL) solution of 0-benzylhydroxylamine (2.46 g; 0.02 mol), the corresponding amine (0.02 mol) and suberoyl chloride was stirred at room temperature overnight. The solvent was evaporated and the-semisolid residue was dissolved in 1000 mL chloroform-methanol (4:1); the resulting solution was washed with water (2 x 100 mL) , 10% hydrochloric acid (3 x 100 mL) , and again 2.0 with water (2 x 100 mL) . Organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was dissolved in methanol (100 ~mL) and 5% Pd-C
was added. The black suspension was shaken under hydrogen pressure (~50 ps~.) overnight. The catalyst was separated by filtration, and the filtrate was evaporated.
The target products were isolated by vcolumn chromatography on silica gel with ethyl acetate-tetrahydrofuran.
3: 0 ' 0 ~ . //
/~ ~Cg2 ?.'C
HOHN 6 \ NHOCH3 Yield 1.1 g (26%) , 1H NN~t (DMSO-D6, 200 Ngiz) , b tppm) WO 95/31977 " PCT/US95/06554 10.93 (s, NHOCH3, 1H); 16.32 (s, NHOH, 1H); 8.66 (s, NHOH, 1H); 3.55 (s, CH;, 3H); 1.91 !t, J=7.6Hz, CH,CO-,4H); 1.45 (m, 4H); 1.20 (m, 4H).
~ \_ s. ~ ~..11 J : C i~~
Yield 1.2 g (21%) . 'H NMR (DMSO-db, 200 MHz) , b (ppm) .10.31 (s, NHOH, 1H); 8.60 (s, broad, NHOH, 1H); 7.57 (d, J=7.6Hz, NH-C6H", 1H), 3.40 (m, CH-NH, 1H); 1.99 (t, J=7Hz , CHZCONHC6H1~ ; 2H) ; 1. 91 ( t , J=7 . 6Hz , G~H.CONHOH, 2H) ;
1.63 (m, 4H); 1.44 (m, 6H); 1.20 (m, 8H).

0 ~ //
/C (CHZ ?--C
HOHN 6 \
N (CH3 ) Yield 870 mg ( 20% ) . 1H NNQt (DMSO-D~, 200 N~Iz ) , b (ppm) 10.31 (s, NHOH, 1H); 8.67 (s, broad, NHOH, 1H); 2.85 (d, J=30Hz, N(CH3)2, 6H) ; 2.24 (t, J=7.4Hz, CHzCON(CH3) , 2H) ;
1.91 (t, J=7.4Hz, CHzC00NHOH, 2H); 1.50 (m, 4H); 1.20 (m, 4H) .
3 0 ~ ~ //
C (CH2 ~--C

~ N NHO H
Yield 1.4 g (27%); 'H NMR iDMSO-db, 200 MHz); b(ppm) 10.31 (s, NHOH, 1H) ;. 8.67 (s, NHOH, 1H) ; 3.40 (2t, CHIN, 4H) ;
2.20 (t, J=7.4 Hz, CHzCON(CH2)s, 2H) ; 1.91 (t, J=7.4Hz, WO 95/31977 _ ~ PCTlIJS95/06554 CH,CONHOH, 2H); 1.10-1.60 ;m, broad, 14 H).
Compound having structure:
0 ~ ~f ' u,~ )..-~
.. 1.
~ L 5 HOgN N~ocx2c~~J
to The chloroform (500 mL) solution of 0-benzylhydroxylamine (1.23 g; 0.01 mol), 0-(trimethylsilyl>hydroxylamine~(1.1 g; 0.01 mol), pyridine t1.6 mL; 1.7 g; 0.02 mol) and suberoyl chloride (1.8 mL; 2.11 g; 0.01 mQl) was stirred at room temperature overnight. The reaction suspension was diluted with methanol (100 mL), washed with 10%
hydrochloric acid ( 3 x 100 mL) : The organic layer was dried over anhydrous magnesium sulfate and evaporated.
The solid residue was subjected to chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1). The yield was 500 mg (17%) . 'H NI~2 (DMSO-db, 200 l~iz) , 8 (ppm) 11.09 (s, NFiOCHZC6Hs, 1H) ; 10.31 (s, NHOH, 1H) ; 8.67 (s, broad, NHDH, 1H) ; 7.36 (s, CbHs, 5H) , 4.76 (s, CHZC6H5, 2H) ;
1.92 (t, Jg7.4Hz, CHzCO-, 4H); 1.45 (m, 4H); 1.20 (m, 4H).
2~
compound having the structure:
3 0 /C (CH2 ). CN
S
HO HN
Into a cooled solution 'of potassium hydroxide (2.24 g;
35 0.04 mol) and O-benzylhydroxylamine hydrochloride in 30 mL of tetrahydrofuran-water (1:1) mixture, 6-bromohexanoyl chloride (3.1 mL; 4.27 g; 0.02 mol) was added. The reaction mixture was stirred at room temperature for one hour. The solvent was evaporated and solid residue was partitioned between chloroform (200 mL) and water (100 mL>. Chloroform layer was washed with 10%
hydrochloric acid (3 x 50 mL) and water (2 x 50 mLi. The organic layer was dried over anhydrous magnesium sulfate and evaporated. The product was purified by crystallization from ethyl acetate-hexanes. The yield of N-benzyloxy-6-bromohexanoyl amide was 4.7 g (?8%). A
dimethylsulfoxide (250 mL) solution of N-benzyloxy-6-bromohexanoyl amide (4.5 g; 15 mmol) and sodium cyanide (7.35 g; 0.15 mol) was heated at 130°C overnight. The solvent was evaporated and solid residue was partitioned between chloroform (300 mL) and water (~00 mL). The chloroform layer was washed with water (5 x 100 mL), dried over anhydrous magnesium sulfate, and evaporated.
The oily residue was purified by column chromatography on silica gel. in ethyl acetate-tetrahydrofuran (4:1) as an eluent. The yield of N-benzyloxy-6-cyanohexanoylamide was 1.62 g (43%). The product was dissolved in methanol (50 mL) and 5% Pd-C (100 mg) Was added. The black suspension was shaken under hydrogen pressure (-50 psi) overnight. The catalyst was isolated by filtration and filtrate was evaporated. ~ The solid-residue was slurried in hexanes (-20 mL) and filtered. The yield of N-hydroxy-6-cyanohexanoylamide was 900 mg (overall yield 30%) : 'H NI~t (DMSO-db, 200 I~iz) , a (ppm) 10.32 (s, NHOH, 1H); 8.65 (s, NHOH, 1H); 2.45 (t,J=7Hz, CHZCN, 2H) 1.93 (t, J=?Hz, CHZCONHOH, 2H);'1.49 (m, 4H); 1.33 (m, 2H).
Compounds ha~ring the structure:
. ~
R C---~(CH2 j--C
n \
OH

WO 95131977 ,. . ~ PCT/US95I06554 General Procedure A diacid dichloride ( 0 . O1 mol ) was added into a cooled (0°C) solution of potassium hydroxide (1.12 g; 0.02 mol) and corresponding amine (0.01 mol) ,in 30 mL of tetrahydrofuran-water (i:1) mixture. The reaction mixture was stirred at room temperature about one hour.
Solvent Was evaporated and the solid residue was partitioned between chloroform (300 mL) and water (300 mL). In some eases a small amount of methanol is necessary to dissolve all solid. The organic layer was washed with 10% potassium hydroxide (3 x 30 mL). The basic water extract was acidified with 10% hydrochloric acid: The precipitate was collected by filtration, dried and purified by crystallization from ethyl acetate or by column chromatography on silica gel iw ethyl acetate-tetrahydrofuran (4:1). The yields are from 20-3?%.
2 0 II , /%
NH C (CH2 ) C ~.
6 . OH
~H l~l~Ht (DN1S0-ds, 200 MHz) ; b (ppm) 11.9? _(s, COOH, 1H) ;

9.84 (s, NH, 1H); 7.57 (d, J=7.4Hz, ortho aromatic protons, 2H); 7.26 (t, J=8.4Hz, meta aromatic protons, 2H); 6.99 (t; J=7.4Hz, para aromatic proton, iH), 2.27 ft, J=7Hz, CHiCONHPh, 2H); 2.18 (t, J=7.2Hz, 2H); 1.52 (m, 4H): 1.28 (m, 4H).
NC
11 /j NH C (CH2 ) C~

'H NMR (DMSO-db, 200 MHz), b(ppm) 11.95 (s, COON, 1H);

10.20 (s, NH, 1H); 8.10 (s, aromatic proton, 1H); 7.75 WO 95/31977 ~ PCT/US95/06554 (m, aromatic proton, 1H); 7.45 ;m, aromatic proton, 2H~;
2.28 (t,J=7.4Hz, CH,CONHAr, 2Hi ; 2.21 l~,J=7.2Hz,~ CH,COOH, 2H) ; 1.45 (m, 4H) ; 1.20 (m, 4H) .
C
...
IAA . ~;~_ _ )' y~C-'H N1~IR (DMSO-db,. 200 NN~iz) , 8 (ppm) 11.95 (s, COOH, 1H) ;
10.29 (s, NH, 1H) ; 7.75 ~s, aromatic protons, 4H) ; 2.33 (t, J=7.2Hz, CHZCONHAr, 2H); 2.18 (t, J=7.4Hz, CH,COOH, 2H) ; 1.53 (m, 4H) ; 1.27 (m, 4H) .
~J 3 II /j O.~N ~ NH C f,CH2 ) C v 'H NN,Bt (DNtSO-db, 200N~iZ) , 11.98 (s, broad, COOH, 1H) ;
10.48 (s, NH, 1H); 8.21 (d, J=9.2Hz, aromatic protons, 2H); 7.82 (d, J=9.2Hz, aromatic proton, 2H)'; 2.36 (t, J=7.4Hz, CHzCONHAr, 2H) ; 2.18 (t, J=7.2Hz, CH~COOH, 2H) ;
1. 55 (m, 4H) ; 1.29 (m, 4H) .~
3 0 ~~ //
N NH C (CH2 ) C

'H NNHt (DMSO-db, 200 Ngiz) , b (ppm) 12.00 (s, broad COOH, 1H); 1Ø24 (s, NH, 1H); 8.38 (d, J=5.8Hz, aromatic protons, 2H); 7.55 (d, J=5.8Hz, aromatic proton, 2H);
2.33 (t, J=7.2Hz, CH2CONHAr, 2H); 2.18 (t, J=7.2Hz, CHZCOOH); 1.52 (m, 4H); 1.27 (m, 4H).
1l ~°
NH
6 ~OH

WO 95/31977 ' PCT'/US95I06554 'H NMR (DMSO-db, 200MHz), b(ppm) 11.95 (s, COON, 1H); 7.58 i.d, J=8Hz); 3.50 (m, CH, 1H); 2.17 (t, J=7.2Hz, CH.COOH, 2H); 2.00 (t, J=7Hz, CH,CONH-, 2H); 1.60 (m, 4H); 1.46 m, 6H); 1.20 (m, 8H).In the same way the following compounds were prepared and characterized:
H
I
n r ~J
_ N II
- \C ( CHZ ) C
// n \ o ~ , ~
wherein n = 4 , 5 , 6 , 7 , and 8 ; R is hydrogen; 2 - , 3 - , and 4-cyano; 2-, 3-, and 4-vitro; 2-, 3-, and' 4-methylcyano; 2-, 3-, and 4-trifluoromethyl; 2-, 3-, and 4-fluoro;
H
I _ .0 II
~C (CHZ n C\
. 0 OH
wherein n = 4, 5, 6, 7, and 8;
H

N\ II
/C (CH ) C
0 2 n \0H
wherein n = 4, 5, 6; 7, and 8;
/ o N N\ II
~C (CH2 ~ C\

WO 95131977 ~ PCT/US95106554 wherein n = 4, 5, 6, 7, and 8;
g N //_ .~ ~ r r' //J mg~ ,n ~ ~o H
wherein n = 4, 5, 6, 7, and 8;

//
(CHZ n C\

wherein n = 4, 5, 6, 7, and 8; _ R /H
. ~ . 0 //
/~ (CHZ )--C\
OH

wherein R is 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3-, and 4-methylaminocarbonyl; 2-, 3-, and 4-dimethylaminocarbonyl; 2-, 3-, and 4-chloro;
2-, 3-, and 4-bromo; 2-, 3-, and 4-iodo; 2-, 3, and 4-methyl; 2-, 3-, and 4 methoxy; 2-, 3-, and 4-hydroxy;
2-, 3-, and 4-amino; and 2-, 3-, and 4-dimethylamino.

WO 95/31977 ~ PCT/US95/06554 Compounds havinS the a.eneral structure:
C
II II //
s \ .=H-, "c ~t C
i~ _ :. I . ~c .. .
:..
wherein n = 4, 5, ~, and 7.
General Procedure A
A pyridine (500 mL) suspension of 0-benzylhydroxylamine hydrochloride (3~.2 g; 0.02 mol) and they corresponding diacid dichloride (0.04 mol) was stirred at room temperature for three days. Water,(10 mL) was added and stirring was continued overnight. The solvent was evaporated and solid residue was purified by column chromatography on silica gel in tetrahydrofuran-methanol.
The diacid product was dissolved in methanol (100 mL) and 5% Pd-C (100 mg) was added. The reaction suspension was shaken overnight under hydrogen pressure (DSO psi). The catalyst was separated by filtration, solid residue was washed with hot methanol (5 x 50 ml). The combined methanolic filtrates were evaporated. Tne solid residue was slurried in acetone and filtered. The yield was iti-20%.
General~ocedure B
A pyridine (S00 ml) solution of 0-benzylhydroxylamine (2.46 g; 0.02 mol) and the corresponding dicarboxylic acid monobenzyl ester monoacid chloride (0.04 mol) was stirred at room temperature overnight. The solvent was evaporated. The semisolid residue was dissolved in chloroform (300 mL) and extracted with 5% hydrochloric acid (2 x 50 mL) , 10%potassium hydroxide (3 x 100 mL) , . and water t2 x 100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The sold residue was purified by column chromatography on silica gel in ethyl acetate. The tribenzyl produce was S dissolved in methanol 1100 mL) and 5% Pd-C ;100 mg; was added. The reaction suspension was shaken under hydrogen pressure (-50 psi) at room temperature overnight. The solid was separated by filtration and washed with hot methanol (5 x 50 mL). The combined methanol filtrates were evaporated to solid residue. The solid residue was slurried in cooled acetone and filtered. The yield of target product was 30-60%.
0 0 ~ 0 C (CH C N C C CH2 ;-.-C .
) / 2 ~ 5 \

H0 O i~
OH

~H NMR (DMSO-d,b, 200MHz) b (ppm)11.53 (s, COOH, .1H) ;
, 2.~1 (t, J=7.2Hz, CH2CON(OH)COCHZ, 4H); 2:18 (t, J=7.OHz, CHzC00H, 4H); 1.52 (m, 8h); 1.22 (m, H). MS (FAH, glycerin) 346(M +
1) Compounds having the structure:
//
~C ~ CCH2 m C' l (CH2 )n ; -C ' (CH2~-C
HO
CH3 CH3 .
A pyridine (500 mL) solution of the monomethyl ester monoacid chloride of dicarboxylic acid (0.02 mol) and N, N ~ - dimethyl -1, cv- dieniinoalkane ( 0 . 01 mol ) was stirred at room temperature overnight. Solvent was evaporated and oily residue was dissolved in chloroform (300 mL).
Chloroform solution was washed with water (3 x 50 mL), 10% potassium hydroxide i3 x 50 mL), 10o hydrochloric acid (3 x 50 mLi, and again with water !3 x 50 mL). The organic layer was dried and evaporated. The oily residue was dissolved in potassium hydroxide (1.2 g; 0.021 mol) in 80% methanol (100 mL). The reaction mixture was refluxed two hours. The solvent was~evaporated and solid residue was dissolved in water (50 mL) and extracted with chloroform (3 x 50 mL). Water solution was acidified to p8--5 and concentrated (to volume of about 10 mL) . The water solution or suspension was cooled down and precipitate was separated by filtration. The solid product was purified by crystallization from -ethyl acetate. The yield was 40-60%.

~

C (CH ) C- N (CHZ ) N-C (CH2)--/ ( 2 I 6 \

. CH3 CH3 ~H
H~

~H NN~t (CDC13, 200 Mtiz)b (ppm) 8.15 (s, broad, COOH.,2H) , ;

3.52 + 3.45 (2s, CHIN,4H) ; 3 .O1 + 2.93 (2s, CH3N, 6H) ;

2.30 (4t, CHZCO, 8 H) .60 (m, 8H) ; 1.32 (m, 8H) ; .

1H NNat (DMSO-db, 200 Nffiz) C3s, , b (ppm) 3.44 + 3.336 + 3 .36 CH2N, 4H); 2.94 + 2.90 + 2.79 (3s, CH3N, 6H); 2.27 2.23 +

+ 2.1.2 (3t, CHZCO; 8H) 1.46 (m, 8H) : 1.23 (m, 8H) ; .

Compounds having the structure:

II II II II
3 0 /C- (CHZ m C-11H-C C-NH-C-(CHZ n C\
xo ~ off A pyridine (500 mL) solution of 6-aminocapric acid (2.6 g; 0 . 02 mol ) and terephthaloyl chloride (2 g; 0 . O1 mol ) was stirred at room temperature overnight (~12 hours), and at 90°C for 23 hours. The solvent was evaporated, and the solid residue was crystallized from water (1O mL) four times. The yield was 800 mg (19%) . 'H NNB2 (DMSO-db, 200 N~i) , 6 (ppm) 12.8 (s, broad, COOH, 2H) ; 8.54 + 7.72 (2t, NH, 2Hi ; 3 .24 + 2.98 (2m, NHCH,, 4H) ; 2.20 - 2 . 03 (2m, CH,CO, 4H); 1.50 (m, 8H); 1.32 (m, 4H).
Compound having the structure:

/-N~
v \ ~i Hc~:
~. o into a mixture of aniline (2.75 g; 0.03 mol), hydroxylamine hydrochloride (2.08 g; 0.03 mol), and potassium hydroxide (5.508; 0.09 mol) in 50%
tetrahydrofuran (100 mL) was slowly bedded at room temperature a tetrahydrofurane (20 mL) solution of terephthaloyl chloride (6 g,; 0:03 moI). The .reaction suspension Was stirred at room temperature for thirty minutes. The solvent was evaporated. The solid residue was slurried in hot methanol (1000 mL) and dried over anhydrous magnesium sulfate: The methanol solution was separated by filtration and filtrate was evapora$xd. The solid residue was slurried in 20 mL cooled methanol and filtered. The white crystals were washed with ether (5 x 50 mL) and dried. The' yield was 4.6 g. (39%) . 'H NMR
(DMSO-db, 200 Ngiz) , b (ppm) 11.35 (s, broad, NHOH, 1H) ;
10.35 (s, NHPh, 1H); 9.19 (s, NHOH, 1H); 8.03 (d, J=BHz, terephthalic protons, 2H); 7.89 (d, J=BHz, terephthalic protons, 2H); 7,82 (d, J=7.4Hz, ortho anilide protons, 2H); 7.34 (t, J=7.4Hz, meta anilide protons, 2H); 7.10 (t, J=7.4Hz, para anilide proton, 1H).
Compound having the structure:
i~
3 5 ~ ~ ~-c$Z-c-c~~ce ~ ~ cg=ca-c~
xaoH

WO 95/319'77 PCf/US95I06554 A solution of 1,4-pherylenediacrylic acid (2.18 g; x.01 mol) in thionyl chloride (50 mL; 81.558; 0:68 mol) was refluxed overnight. The excess of thionyl chloride was evaporated. The solid was dissolved in tetrahydrofuran (20 mL), and added to a cooled (0°C) solution of potassium hydroxide (1.12 g; 0.02 mol) and aniline in 50%
tetrahydrofuran. The reaction mixture was stirred at room temperature for thirty minutes. The solvent was evaporated. The solid residue was slurried in water and filtered. White crystals were dissolved in a small amount of methanol and purified on a silica gel column in tetrahydrofuran. The yield was 315 mg (10%) . 'H NN~2 (DMSO-d6, 200 MHz); b(ppm) 10.80 (s, NHOH, 1H); 10.23 (s, NFiPh, 1H); 9.09 (s, NHOH, 1H); 7.69 (d, ~T=7.6Hz, ortho anilide protons, 2H); 7.64 (s, phenylene protons, 4H), 7.5,5 (d, J=15.8Hz, PhNHOCCH=CH-, 1H); 7..40 (d, J=15.8Hz, HONFiOCCH=CH-, 1H); 7.33 (t, J='7.8Hz, mesa anilide protons, 2H); 7.06 (t, J=7.2Hz, para ani.lide protons, 1H); 6.89 (d, J=15.8Hz, PhNHOCCH=CH-, 1H) 6.51 (d, J=15.8Hz, HOHNOCCH=CH-, 1H).
Compounds having the stricture:
0 ~ CH
R/C ~ 2 ~ C\
R
wherein n = 4, 5, 6, 7, and 8.
A chloroform solution of triethylamine (1.4 mL; 1.0 g;
0.01 mol), the corresponding amine (0.01 mol) and diacid dichloride (0.005 mol) was stirred at room temperature for five hours. If ~ the reaction mixture was clear, it 35. was washed with water (5 x 100 mL) . The organic layer was dried over anhydrous magnesium sulfate and evaporated to a solid residue. If in the course of reaction a -SO-precipitate was formed, the precipitate was separated by filtration. White crystals from Tilt=ation or solid residue from evaporation were crystallized from ethyl acetate, tetrahydrofuran, methanol, or their mixture.
The yields were from 60-90%.
f aC ,,\ ,'/ ~ KH_~ ~! CHZ , C~.''-.Yv o , l . 0 Nli----,.y. //,-- a 3 ~~
'H Nit (DMSO-db, 200 MHz) , b (ppm) 10.23 (s, NH, 2H) ; 7.82 (d, J=9Hz, aromatic protons, 4H), 7.60 (d, J=9Hz, aromatic protons, 4H) , 2.31 (t, J=7.4Hz, C,HZCO, 4H) ; 2.61 (m, 4H); 1.32 (m, 4H).
(CHZ 6 C\
'H NNBt (DMSO-db, 200 MHz) , b (ppm) 10.48 (s, ° NH, 2H) ; 8.18 (d, J=9.2Hz, aromatic protons, 4H); 7.81 (d, J=9.2Hz, aromatic protons, 4H0; 2.37 (t, J=7.2Hz,~ CH2C0-, 4H)~; 1.60 (m, 4H); 1.33 (m, 4H).
o NCCHZ ~ ~ NHS //
// (CH2 6 C\
O ~ ~ ~ CH2CN
'H Nl~t (DMSO-db, 200 MHz) , 69 .91 (s, NH, -2H) , 7.58 (d, J=8.6Hz, aromatic protons, 4H); 7.26 (d, J=8.6 Hz, aromatic protons, 4H); 3.94 (s, CH2CN, 4H); 2.29 (t, J=7.4Hz, CH2C0-, 4H): 1.60 (m, 4H); 1.31 (m, 4H).

H3c~roc ~ ~ xH~ //
~/C ( CHZ 6 C \
C IiH ~ ~ COFHCB3 wo 95131977 PCT/US95106554 'H NMR (DMSO-db, 200 MHz), b(ppm) 10.08 (s, CONHAr, iH;;
7.79 (d, J=8.6Hz, aromatic protons, 4H); 7.63 id, J=BHz, aromatic protons, 4H) , 7.22 (s, H3CHNC0-, 2H) ; 3.32 ;s, CH3, 6H); 2.31 (t, J=7Hz, CH,C-), '6H); 1.59 (m, 4H); 1.31 (m, 4H) .
V
H~~ 3~IC~C --~ ~ , j--:ZH ~
1~ w :; ~C (CH., i ~C , ;; y 6 '.NH --~% -~OH::O~
'~> i ~H NMR (DMSO-db, 200 MHz) , b (ppm) 10.90 (s, broad, NHOH, 2H>; 10.05 (s, NFiAr, 2H); 8.90 (s, broad, NHOH, 2H); T.68 (d, J=9Hz, aromatic protons, 4H); '7.62 (d, J=9Hz, aromatic protons, 4H) ; 2.31 (t, J=7.2Hz, CHiCO-, 4H) ; 1.59 (m, 4H); 1.30 (m, 4H).
~ 0 ~NIi\ . //
C (CHZ ) C . N .
N // 6 \
0 NH ~ \
'H NMR (DMSO-db, 200 MHz) , a (ppm) 10.06 (s, broad, NH, 2H); 8.71 (d, J=2:6Hz, aromatic protons, 2H); 7.31 (d +
d, aromatic protons;. 2H); 2.32 (t, J=7.4Hz, CH2C0-, 4H),-1. 59 (m, 4H)~ ; 1. 33 (m, 4H) .
NH \ ~l S ~/~ (CHZ 6 .C\ S
p NH
N
'H NNgt (DMSO-db, 200 MHz) , b (pgm) 12.00 (s, broad, NH;
2H),; 7.43 (d, J=3.6Hz, aromatic protons, 2H); 7.16 (d, ' J=3.6Hz, aromatic protons; 2H) ; 2.41 (t, J=7.2Hz, CHZCONH-, 4H) 1.58 (m, 4H) ; 1.28 (m; 4H) .

In the similar manner, the following compounds wer--__ prepared and characterized:
;;
NH
', ' C (,~:,a-.
i.. .. :.
:J
1~ N
wherein n = 4, 5, 6, 7, and 8;
all compounds are symmetrical wherein R is 2-, 3-, and 4 cyano; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-vitro, 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3- and 4-methylaminocarbonyl; 2-, 3-, and 4 dimethylaminocarbonyl; and 2-, 3-, and 4-trifluoromethyl;
R p NHS //
(CHZ )6 C ~
0 NH ~ ~ R .
wherein R is 4-hydroxylaminocarbonyl; 4-methoxycarbonyl;
2-, 3-, and 4-chloro; 2-, 3-, and 4-fluoro; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2,3-difluoro; 2,4-difluoro; 2,5-difluoro; 2,6-difluoro; 1,2,3,-trifluoro, 3,4,5-triflubro; 2,3,5,6-tetrafluoro;
2,3,4,5,6-pentafluoro.
p p NH ~ //
CH Z )6 C ~
0 . . NH \
N

NH \ . . //
(CH2 )~ C~
p HN

WO 95/31977 ~ . PCT/US95106554 ,. C
.a \ //
C:-i - ) f // _ ~ ~ _ \
~, ~_r :~ -~
:-i"~1 to N~N\
;' ;CH., ) C~
// ~ a N \\
C

N ~
N . NHS
compounds having the structure:
p\ . ~ //
~C (eH2 ~ C~
HO RN Ft wherein n = 4, 5, 6, 7, and 8.
general ~,rocedure A
A diacid dichloride (0.01 mol) was added to a stirred solution of potassium hydroxide (1.68 g; 0.03. mol), hydroxylamine hydrochloride (0.7 g; 0.01 mol), and the corresponding aniline (0.01 molj in 50% tetrahydrofuran (1.00 mL). The resulting reaction n~iixture was stirred at -WO 95/31977 ~ PCT/LTS95/06554 room temperature thirty minutes, and solvent was evaporated to solid residue. The solid r-esidue was slurried in methanol (--100 mL) and dried over anhydrous magnesium sulfate. The methanol solution was separated by filtration and evaporated to a solid residue.. The product was purified by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (in most cases 3:1;.
The yields were 15-30%.
General ,procedure B
A solution of corresponding monomethyl ester of dicarboxylic acid (0.01 mol), oxaloyl chloride (0.03 mol), and a few drops DMF.in benzene (500 mL) was stirred at room temperature overnight. The solvent .was evaporated and the oily residue was dissolved in dry benzene (3 x 50 mL) and evaporated again. The tetrahydrofuran .(SO mL) solution of monoester monoacid chloride of the corresponding di.carboxylic acid was slowly added to a cooled solution of the corresponding amine (0.01 mol) and pyridine (1.6 mL; 1..6 g.; 0.02 mol) in tetrahydrofuran f200 mL). The reaction mixture was stirred at room temperature for an hour. The solvent was evaporated, the reside was dissolved in chlorofo~n (300 mL), and the chloroform solution was washed with 10%
hydrochloric acid (3 x 50 mL), 10% potassium hydroxide (3 x 50 mL), and water (3 x 50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated, yielding the pure monoester monoamide of dicarboxylic acid. The product was dissolved in 80% methanol with potassium hydroxide (0.56 g; 0.01 mol). The reaction mixture was refluxed two hours and evaporated to solid residue. The residue was dissolved in water (-20 mL) and acidified to ~pH 5 with 10% hydrochloric acid. The monoacid monoamide of the dicarboxy7:ic acid was isolated by filtration of precipitate or extraction water solution with chloroform. The isolated monoacid monoamide of the WO 95/31997 , _ PCT/US95106554 dicarboxylic acid was mixed together with an equivalent amount of 0-benzylhydroxylamine and 1,3-dicyclohexyl-carbodiimide in pyridine '--100 mL per 0.01 mol of 0-benzylhydroxylamine) and was stirred at room temperature S overnight. The solvent was evaporated and the solid residue was partitioned between chloroform (500 mL) 'and.
10% hydrochloric acid (300 mL). The crganic layer was washed with water (3 x 100 mL) and dried over anhydrous magnesium sulfate. The solvent was evaporated to solid residue. The solid residue was dissolved in large amounts of tetrahydrofuran and filtered through a short column of silica gel. The crude product was dissolved in methanol (100 mL) .and 5% Pd-C was added. The reaction suspension was shaken under hydrogen pressure (-50 psi) overnight. The catalyst was separated by filtration and filtrate was evaporated to solid residue. The solid residue~was slurried in hexanes and filtered. Mostly pure product was isolated in this way. If necessary further purification was achieved by column chroma ography on silica gel with ethyl acetate tetrahydrofuran: The yields were from 35% ao 65%.
GenFral grocedurg,C
A pyridine (500 mL solution of 0-benxylhydroxylamine (1.23; 0.01 mol), the corresponding amine (0.01 mol), and the dichloride of the dicarboxylic acid (0.01 mol) was stirred at room temperature overnight. The solvent was evaporated and the white solid residue contains, judged by 'H NN~t, two symmetrical amides and a target unsynanetrical one. The solid residue was slurried in methanol and dried over anhydrous magnesium sulfate. The filtrate was evaporated and the solid residue was dissolved in methanol 0100 mL). Into the methanol ' solution 5% Pd-C (100 mg) was added and the black suspension was shaken under hydrogen prAssure (~50 psi) overnight$x The catalyst was separated by filtration and the filtrate was evaporated. The product was isolated by column chromatography on silica with ethyl acetate-tetrahydrofuran. The yields were from 20% to 35%.
General ,procedure D
A chloroform solution of triethylamine (3 mL; 2.18 g;
0.0215 mol), the corresponding amine (0.01 mol;, 0-trimetYiylsilyl)hydroxylamine (1.05 g, 0.01 mol), and the corresponding diacid chloride of the dicarboxylic acid (0.01 mol) was stirred at room temperature overnight. The solvent was evaporated, the residue was dissolved in methanol (--10 mL), and into the methanol solution 10% ammonium chloride (~10 mL) was added. The resulting suspension was stirred at 50°C for two hours.
The solvent was evaporated. The solid residue was slurried in methanol (300 mL) and dried over anhydrous magnesium sulfate. The methanol solution was separated by filtration and evaporated to a solid residue. The product was isolated by silica gel column chromatography with ethyl acetate-tetrahydrofuran. The yields were 20-33%.

~I . /%
, NH G (GH2 )6 NHOH
C H N
Elemental analysis: Calc. 63.62 7.63 10.60 Found 63.58 7.59 10.48 'H NN~2 (DMSO-ds, 200 Ngiz) , b (ppm) 10.31 (s, NHOH, 1H) ;
9.83 fs, NHPh, 1H); 8.64 (s, NHDH, 1H); 7.57- (d, J=8.2Hz, ortho aromatic protons, 2H); 7.26 (t, J=8.4Hz, meta aromatic protons, 2H), 6.99 (t, J=?.4Hz, para aromatic protons, 1H) ; 2.27 (t, 'J=7.4Hz, CHZCONHPh, 2H) ; 1.93 (t, J=7.2Hz, CH=CONHOH, 2H); 1.52 (m, 4H); 1.26 (m, 4H). MS
(Fab, Glycerin) 172, 204, 232, 249, 265, (100%, M + 1).
n I ~/.
. Nu _ .~ti_.
.~ E \
_'; HC
CN
~H NMR (DMSO-db, 200 MHz), b(ppm) 10.31 (s, NHOH, 1H);
10.08 (s, NHPh, 1H); 8.64 (s, NHOH, 1H); 7.78 (d, J=7.6Hz, aromatic protons, 1H); 7.66 (t, J=7.4Hz, aromatic protons, 1H); 7.48 (d, J=7.8Hz, aromatic protons, 1H); 7.29 (t, J=7.4Hz, aromatic protons, 1H);
2.34 (t, J=7Hz, CHZCONHiAr, 2H) ; 1.93 (t, J=7.4Hz, CH~CONHOH, 2H); 1.58 (m, 4H); 1.27 (m, 4H).
NC
I I
~~NHTC (CHZ ~6 C
NHOH
1H NMR (DMSO-d6, 200 MHz) , b (ppm) 10.31 (s, NHOH, 1H) ;
10.21 (s, NHPh, 1H) ; 8:65 (s, NFiOH, ~ 1H) ; 8.09 (s, aromatic proton, 1H); 7.77 (m, aromatic proton, 1H); 7.49 (m, aromatic proton, 1H); 2.31 (t, J=7.2Hz, CHZCONHAr, 2Ii) ; 1.93 (t, J=7.2Hz, CHZCONI30H, 2~I) ; 1.51 (m, 4H) .

(~ /%
NH c (cx2) c 6 \
.. v NHOIi 'H NN~t (DMSO-ds, 200 N~iz) , b (ppm) 10.35 (s, NFiAr, 1H) ;
10.31 (s, NHOH, 1H); 8.63 (s, NHOH + aromatic proton 2H);
7.88 (d, J=BHz, aromatic protons, 2H); 7.57 (t, J=BHz, WO 95I319T! ~ PGT/US95/06554 -5a-aromatic proton, 1H) ; 2.33 (t, J=?.6Hz, CH,CONHAr, 2H; ;
1.93 (t, J=?.4Hz, CH,CONHOH, 2H) , 1.52 (m, 4H) ; 1.2? (m, 4H) .
.. , ;, -n ,.
' ~ NH - _ NH - _ t=H..' C
- c uHVH
'H NMR (DMSO-da, 200 MHz), b(ppm) 10.33 (s, NHOH, 1H);
10.15 (s, NHAr, 1H); 10.09 (s, NHPh, 1H); 8.66 (s, NHOH, 1H); ?.91 (d, J=8.6Hz, aromatic protons, 2H); ?.76 (d, J=?.8Hz, ortho aniline protons, 2H); 7.71 (d, J=8.6Hz, aromatic protons, 2H); ?.33 (t, J=?.6Hz, meta anilide protons, 2H); ?.0? (t, J=?.4Hz, para anilide protons);
2.33 (t, J=7.5Hz, CHZNHAr, 2H); 1.93 (t, J=?.2Hz, CHZCNHH, 2H) ; 1.51 (m, 4H) ; 1.28 (m, 4H) .

/j .
NH 0 (CH2 )6 C\
NHOH
F
'H N~1R (DMSO-d~, . 200 Liz) , b (ppm) 10.32 (s. NHOH, 1H) ;
10.21 (s, NHAr, 1H); 8.65 (s, NHOH, 1H); ?.31 (d of d, J=lOHz(2.2Hz), aromatic proton , 2H); 6.84 (t of t, J=9 .4Hz (2.4Hz) , aromatic protons, 1H) ; 2.29 (t, CH2CONHAr, 2H); 1.93 ~(t, J=7.2Hz, CHzCONHOH, 2H); 1.51 (m, 4H); 1.26 (m, 4H) .
In the same manner the following compounds were prepared and characterized:
R
NH . 0 l/
C (.CH2 ) C
// n wherein n = 4 , 5 , 6 , 7 , and 8 ; and R is 2 - , 3 - , and 4 -cyano; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-vitro;
2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbanyl; 2-, 3-, and 4-methylaminocarbonyl; 2-,~ 3-, and 4-dimethylaminocarbonyl; and 2-~, 3-, and 4-trifluoromethyl; ' r . NHS //_.
'/C -r--- ( C H 2 ) C
s ~
' 0 NHOH
~5 wherein R is 4-hydroxylaminooarbonyl; 4-methoxycarbonyl;
4-tetrazoyl; 2-, 3-, and 4-chloro; 2-, 3-, and 4-fluoro; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy;
2,3-difluoro; 2,4-difluoro; 2,5-ditluoro; 2,6-difluoro; 1,2,3-trifluoro; 3,4,5-trifluoro; 2,4,5-trifluoro; 2,4,6-trifluoro; 2,3,6-trifluoro; 2,3,5,6-tetrafluoro; 2,3,4,5,6-pentafluoro; 2-,_ 3-, and 4-phenyl; 2-, 3-, and 4-benzyloxy; 4-hexyl; and 4-t-butyl;
~ 0 //
C (CH 2 ~--- C
'~ N NHO H
NH\ /~
~ ~ ~~ (CH2 ) C

~ NHOH

WO 95/31977 ~ PGT/US95I06554 '0J-Compounds having ~he structure:
F
..,\., ., //_ ~., ~i~. ;
// ' r. ,. ~ _ , C
wherein n = 4, 5, 6, 7, and 8; and R is hydrogen or methyl.
A diacid dichloride (0.01 mol) was added into a stirred solution of potassium hydroxide (1.68 g; 0.03 mol), aniline or N-methylaniline (0.01 mol), and3dimethylamine hydrochloride. (0.805 g; 0.01 mol) in 50% tetrahydrofuran (100 mL). The reaction mixture was stirred. thirty minutes at room temperature. The solvent was partitioned between chloroform (400 mL) and water (300 mL). The organic layer was washed with 10% hydrochloric acid (3 x 100 mL), 10% potassium hydroxide (3 x 100 mL), and water (2 x100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was slurried in hexanes and filtered. The yield were 25-34%.
g /.
N \ //
//C (GHZ ~ G\
0 N (CH3 )2 ~H NN~t (DMSO-db, 200 Ngiz) , 6 (ppm) 9 . 82 (s, NHPh, 1H) ; 7.58 (d, J=7.6Hz, ortho aromatic protons, 2H); 7.26 (t, J=7.4Hz, meta aromatic protons, 2H); 6.99 (t, J=7.4Hz, para aromatic proton, 1H); 2.85 (d, J=28Hz, N(CH3)Z, 6H);
2.28 (t, J=7.2Hz, CH2C0, 2H); 2.24 (t, J=7.4Hz, CHZCO, 2H); 1.51 (m, 4H); 1.29 (m, 4H).

y J N \ ' //
fC:i2 // r:
,-'H NMR (DMSO-db, 200 MHz) , b (ppm) 7. 30 (m, CoHs, 5H) ; 3 . i3 (s, H3CNPh, 3H) ; 2.83 (d, J=26Hz, N(CH3),, 6H) ; 2.17 (t, J=7.6Hz, CH.,CON(CH3)2, 2H); 1.98 (t, J=7.4Hz, CH,CON(CH3)Ph, 2H); 1.41 (m, 4H); 1.11 (m, 4H).
Compounds havincr the structure 25 wherein R" R2 are NHOH.
A solution of 18.4g (175 mmol) of HZN-OSiMe3 in 100 ml abs . CH2Clz was slowly added to a stirred solution of the corresponding diacid chloride of the dicarboxylic acid ( 10g, 43 . '~ mmol ) in 250 ml abs . CHZC12 which was kept at -78°C under Argon. After the addition was complete, the mixture was allowed to warm to' room temperature with stirring. A white precipitate formed during this process. After 2h at room temperature, the mixture was heated to reflex for 30 min. to complete the substitution reaction. It was then agaiw cooled at -78°C, whereupon 10 ml of abs. MeOH were added with stirring. The cooling was then removed and the mixture was .allowed to come to room temperature; during which period much more white WO 95/31977 ~ PGTILJS95I06554 precipitate appeared. After an additional 10 ml of MeCH
had been added, the reaction was again heated to refiux for 30 min. The precipitate was filtered off and stirred with 100 ml of 0.2 N HC1 for 2h. . The product was ther_ filtered, washed with water and dried in a vacuum X0.2 torn room temperature) over CaCl,. As the nmr spectrum (in db-DMSO) still indicated, the presence of water in the product after this process, the product was stirred with 40 ml of ~ dry acetone, filtered again and dried in the same fashion. The water peak in the nmr spectrum then decreased to the normal size expected for commercial db .DMSO. Yield: 8.8g (91%).
~H-NMR (db-DMSO, 200 MHz) b (ppm) 11.25 (b~. s, 1H) and 10.75 (br. s, 1H) (N-$); 9.1 (br. s, 2H, O-H); 7.9 (s, 1H, CZ-_H) ; ? . 7 (~m, 2H, C4-_H, C6-_H) ; 7 _ 5 (m, 2H, Cs-H, Ar-CH=CH_-CONHOH); 6.5 (d, J=16 Hz, 1H, Ar-CH= ) MS (C1) . M+1 223, 179, 161. Found: C, 54.96; calc.:
C, 54.05%.
In a similar manner the known dicarboxylic acids corresponding to compounds having the following structures, wherein R, and Ri are OH, were converted to their acid chlorides and then to the bis-hydroxamic acids and were also characterized by NMR and mass spectroscopy:

' II
Rl - C
and _6~_ ~_- _ _'-' C.- F:.:
~~
1 =~ ~1 T T
~y N
JJ1~~,..

pCT/(TS95106554 WO 951319??

Compounds having the structure:

R-C-N- (CH,)" -C-NH-OH
H
7-Henzoylamidoheptanoylhydroxamic acid, R _- phenyl, n=6.
In a 25 mL Mask, a solution of 0.571 g of o-aminoheptanoic acid with 0.3145 g NaOH in 12 mL water was chilled to 0°C, and than 0.5 mL of benzoyl chloride in 8 mL dry THF was added dropwise over 30 minutes. After 3.5 hrs stirring the THF was evaporated and the solution was acidified to pH 1. The resulting precipitate of 7-benzolylaminoheptanoic acid was collected and washed with ether. It was characterized by NMR and mass spectroscopy 24 (M+1=250). Then 0.20 g of this amide acid was treated f or 3 hours with 0.1750 g of carbonyl diimidazole in 10 mL dry THF. To this stirring solution was added 0.1114 g of hydroxylamine hydrochloride, and ~he..solution was stirred overnight at zoom temperature. Then 3 mI of 0.1 N HC1 was added, the THF was evaporated, and the residue was taken up in 5 mL ethyl acetate 'and 3 mL brine. The produce amide hydroxamic acid was preset as an ivory colored solid in the organic layer; it was collected by filtration in 60% yield. It was characterized by NMR and mass spectrum fM+1=265) and had m.p. =105°C.
In a similar fashion analogs were~prepared with n=5 or 6, and with R=p-cyanophenyl, m-cyanophenyl, and thiophenyl, by the use of the appropriate carboxylic acid chloride and 7-aminoheptanoic acid or 6-aminohexanoic acid in the first step.

WO 95131977 ~ PGT/US95106554 Compounds having the structure:

R-C-N- (CH;)" -C-NH-OH
H
Suberoyl-(4-pyridyl)-amide hydroxamic acid, R - 4-pyridyl, n=6.
To an ice-cold solution of 6 mL suberoyl chloride in 20 mL THF was added 1.37 mL methanol and 4.7 mL
triethylamine in 40 mL THF dropwise with stirring. After 19 hours a solution of 3.2032 g 4-aminopyridine and 4.'7 mL triethylamine in 250 ~mL THF was added ~dropwise with stirring and ice cooling. After 24 hours a small amount of white solid was removed by filtration, the THF was evaporated, and the crude product was chromatographed to .20 afford 2.8879 g of the methyl ester of this amide ester was added to a solution of 0.9866 g hydroxylamine hydrochloride in 17 mL methanol with 0.8887 g NaOH, and the filtered solution was allowed to stand at room temperature for two days. The precipitated salt to the hydroxamic acid was washed. with a little ethanol and stirred in 0.1242 g acetic 'acid in 10 mL water. After 48 hours 0.2291 g of the hydroxamic acid had crystallized, and it was collected and recrystalli2ed from methanol to afford the pure product, m:p. 202-203°C. It was characterized by NNgt and mass spectrum (M+1=266).
In a similar fashion the 2-pyridyl and 3-pyridyl analogs were prepared, using the appropriate amines.

WO 95/31977 ~ PCT/US95/06554 Compounds having the formula:
c o s i1 II
R-NH-~-N-(CH_in -C-NH-OH
H
m-Chloropheaylureido-6-hexanohydroxamic acid, R - m-chlorophenyl, n=5.
To 3.0 g of 6-aminocaproic acid in 150 mL THF was added 3.5 mL triethylamine, then 3 mL m-chlorophenyl isocyanate. After overnight standing the solution was filtered and concentrated by evaporation. Then partitioning between water and ether, followed by acidification of the aqueous layer to pH 3.0, afforded a precipitate of the ureidocarboxylic acid in 35% yield, characterized by NMR and mass spectrum (M+1=285). This was then converted to the hydroxamic acid product by treating 0.0418 g of the acid with 0.321 g carbonyl diimidazole in 25 mL THF. After 2 hours at room temperature, the solution was treated with 0.1948 g hydroxylamine hydrochloride- and stirred for 20 hours.
Then 15 mL 0.1 N HC1 and 2'S mL ethyl acetate were added and the THF was evaporated. The product appeared as crystals is the organic layer, and wag collected in 38~c yield. It had m.p. 162-163°C, and was characterized by NMR and elemental analysis: C, 51.62; H, 5.82; N, 13.47.
Calc'd C, 52.0; H, 6.05; N, 14.00.
In a similar fashion the unsubstituted phenyl analog was prepared from phenyl isocyanate.

WO 95131977 . PCT/US95/06554 Benzidine Mol. Optimal Reactive CPD Structure Weight Conc.luM) Cells l%) H

O
C /
C

- ( CHI ) o-/

O
OH

iVH

1 n = 4 (known 236 80 70 compound) 2 ' n = 5 250 20 . 84 3 n = 6 264 2.5 70 4 n = 7~ 278 20 8 n = 8 292 20 15 H

~ ~ C
~

- (CHI) 6-cN ~/ ~

OH

.NC ~
/~

(CHI)b-\
~, OH

H

/%
8 ~ - (CHI) 6- 294 12 . 5 32 ~ .

O OH

TABLE 1 (continued) Benzidine Mol. Optimal Reactive CPD Structure Weictht Conc.luM) Cells l%) H

\

- -9 /C (CHi)6 \ 225 50 20 OH

H

CHZO

(CHI) 6 ~

OH

(H3C) zN' /O
/

11 // - ( CHI ) 6-C 216 6 0 5 3 \

O
NHOH

HOC
C~

- (CHZ) 6-/ ~

O
NHOH

-(CHi)6-C~

/

NHOH

O
~

14 NC ( CHZ ) s-C 15 6 12 5 3 0 'NHOH

/ - (CHz) 6-~ 218 20 43 O NHOH

WO 95131977 ~ PCT/US95106554 TABLE 1 (continued) Benzidine Mol. Optimal Reactive CPD Structure Weight Conc.fuM) Cells f%) /O
16 ~~ - (CHI) 6-C\ 270 8 35 O NHOH
17 C-(CHZ)b-C\/ . 256 62 30 O/ \NHOH
( cH, ) 3c° ~ ~~
18 /~-(CHI)6- \ 260 31 38 O NHOH
CHI /
19~ ~ ~ - (CHI) 6-C~ 278 5 24 CH -C /
-( I)6 ~
O NHOH
20 R = 4-methyl 273 20 52 21 R = 4-cyano 289 7 70 22 R = 3-cyano 289 5 55 23 R = 2-cyano ' 289 16 65 24 R = 3-nitro 309 5 30 TABLE 1 (continued) Benzidine Mol. Optimal Reactive Cep Structure Wei t Conc.luM) Cells (%) 25 R = 4-nitro 309 0.8 30 26 R = 3-trifluoromethyl 332 30 30 27 R = 4-trifluoromethyl 332 5 47 28 R =~2-amino 279 20 54 29 R = 4-cyanomethyl 303 1 30 30 R = 3-chloro 298.5 2 33 31 R = 4-azido (Nj) 304 2 47 32 R 2-fluoro 282 4 65 =

33 R 3-fluoro 282 1 25 =

34 R 4-fluoro 282 4 43 =

35 R 4-benzyloxy 370 4 20 =

36 R 4-methyoxycarbonyl 322 4 28 =

37 R 4-methylaminocarbonyl 321 30 16 =

38 R 2-bromo 343 8 45 =

39 R 2-chloro 298.5 4 34 _ 40 R 4-bromo 343 1.6 47 =

WO 95/31977 ~ PCTNS95/06554 TAB- (continued) Benzidine Mol. Optimal Reactive CPD Structure Weight Conc.(uM) Cells (%) g --41 R = 2,3-difluoro . 300 8 24 42 R = 2,4,5-trifluoro 318 8 36 43 R = 2,3,6-trifluoro 318 31 53 44 R = 2,4,6-trifluoro 318 16 47 45 R = 2,4-difluoro 300 6 60 ' 46 R = 2,3,4,5,6-pentafluoro 354 31 53 47 R = 3,4-difluoro 300 4 ~ 61-48 R = 3,4,5-trifluoro 318 8 55 49 R = 2,5-difluoro . 300 4 70 50 R = 3,.5-difluoro 30Q 2 ~3 51 R = 2-methoxy 294 8 36 52 R = 3-methoxy 294 6 38 53 R = 4-methoxy 294 6 37 . .

54 ~- (CHi) 6-C 290 20 40 p I'lHOH

-?2-TABLE 1 (continued) Benzidine Mol. Optimal Reactive CPD Structure Weight Conc.luM) Cells (%1 H
N O
55 ~ C- ~ 256 30 53 v O NHOH
H
R \ v //°
~~ C CHZ ) s-O R
,_ 56. R - 4-trifluoromethyl 460 50 20 5? R = 4(N)-hydroxylamino- 442 8 10 carbonyl 58 R = 4-cyanomethyl 402 50 25 59 R = 2,4-difluoro 396 500 ' 54 60 R = 2,6-difluoro 396 100 21 61 R = 3,5-difluoro 396 125 31 62 R = 2,3,6-trifluoro 432 250 28 63 R = 2,4,6-trifluoro 432 125 35 64 R = 2,3,4,5,6-pentafluoro 504 125 13 65 R = 4-vitro , 414 25 14 TABLE 1 (continued) Benzidine Mol. Optimal Reactive CPD Structure Weight Conc.fuM) Cells l%) \~ CH3 CH3 66 ~ -CH- (CHz) s-CH-C 270 1250 80 ( H3C ) zN ~ ( CHI ) z 6 7 ~ -CH- ( CHz ) 4-CH- // 2 5 6 2 5 0 0 9 0 ('H3C ) zN ~ N t CHa ) z 68 \\-(CH ~ -CH-(CH ) -C/ 204 125 ~ 56 z~ 2 2 z HO ~ ~ NHOH
CONHOH
6 9 ~- ( CHz ) 5-CH- ( CHz ) s-C 3 3 3 6 0 ~ 4 0 HOHN ~ NHOH
70 ~C- (CHz) ~~ HF.(CHz) z-C ~ 226 160 19 HOHN \ F \ NHOH

WO 95/31977 ~ PCT/US95/06554 TABLE 1 (continued) Benzidine Mol. Optimal Reactive CPD Structure Weight Conc.(uM1 Cells (%) N
/ H ~ . // ..
~~ - ( CHZ ) o-~
O NH~
s 71 n = 4 310 100 8 72 n = 5 324 250 ' 10 73 n = 6 338 50 7 74 n = 7 352 100 10~
75 n = 8 366 100 10 O ~ -NHOH
HONH-C-O
II
H=CH-C-NHOH
HONH-CH=CH-C-NHOH
HONH-~-CH=CH

i i -NH- ( CHI ) s-~ NH-OH
O
79 283.3 3 45 WO 95131977 ' P~/pS95/06554 TABLE 1 (continued) Benzidine Mol. Optimal Reactive CPD Structure Weight Conc.(uM) Cells l$) N-H ~~
C \ i-NH- ( CHZ ) 5-C-NH-OH
O
80 284.74 3 32 _7 Induction of Differentiation of HL-60 Mol. Optimal NBT

CPD Weight Conc.tuM? Positive 6 ~ 274 20 30 22 ~ 289 1.? ~ 28 3.6 322 1 32 31 . 304. 2.5 ?

29 ~ 303 1 ~ 15 43 ' 318 2 20 ?? 222 4 20 78 248 . 20 12 Induction of Diff.~rentiaticn of MELC
Mol. Optimal NHT
CPD Wei,3ht ;.onc . f~~~ positive ~ % ) WO 95/31977 pGT/US95/06554 Ref erences:
1. Sporn, M.H., Roberts, A.H., and Driscoll, ,:.5.
(1985; in Cancer: Principles and Praccic~ c=
S Oncolocrv, eds. Hellman, S., Rosenberg, S.A., and I3eVita, V.T. , Jr. , Ed. 2, (J.H. Lippi::cott, Philadelphia), P. 49.
2. Breitman, T.R., Selonick, S.E., and Collins, S.J.
(1980) Proc. Natl. Acad. Sci. USA 77: 2936-2940.
3. Olsson, I.L. and Hreitman, T.R. (1982) Cancer Res.
42: 3924-3927.
4. Schwartz, E.L. and Sartorelli, A.C. (1982) Cancer Res. 42: 2651-2655. , 5. Marks, P.A., Sheffery, M., and Rifkind, R.A. (1987) Canr~ Res. 47: 659.
6. Sachs, L. (1978) Nature (Load.) 274: 535.
7. Friend, C., Scher; W.,. Holland, J.W., and Sato, T.
(1971) Proc. Natl. Acad S i (USA) 6~8: 378-382.
8. Tanaka, M., Levy, J., Terada, M., Hreslow, R., Rifkind, R.A., and Marks, P.A. (1975) Proc. Natl.
Acad. Sci. (USA) T2: 1003-1006.
9, Reuben, R.C., Wife, R.L., Breslow, R., Rifkind, R.A., and Marks, P.A. (1976) Proc. Natl. Acad. Sci.
(USA) 73: 862-866.
10. Abe; E., Miyaura, C., Sakagami, H., Takeda, M., Konno, K. , Yamazaki:, T. , Yoshika, S. , and Suda, T.
(1981) Proc. Natl. Acad Sci (USA) 78: 4990-4994.

WO 95131977 . PCT/US95/06554 _79_ 11. Schwartz, E.L., Snoddy, J.R., Kreutter, D., Rasmussen, H., and Sartorelli, A.C. !1983) Proc. Am.
Assoc. Cancer Res. 24: 18.
12. Tanenaga, K., ~Hozumi, M., and Sakagami, Y. ;i98C
Cancer Res. 40: 914-919.
13. Lotem, J. and Sachs, L. (1975) Int. J. Cancer 15:
731-740.
14. Metcalf, D. (1985) Science, 229: 16-22.

15. Scher, W., Scher, H.M., and Waxman, S. (1983) Exp-Hematol. i1: 490-498:

16. Scher, W., Scher, B.M., and Waxman, S. (1982) Biochem. & Hiophys. Res. Comm. 109: 348-354.

17. Huberman, E. and Callaham, M.F. (1979) _Proc. Natl.
Acad. Sci. (USA) 76: 1293-1297.

18. Lottem, J. and Sachs, L. (1979) Proc. Natl. Acad.
Sci. (USA) 76: 5158-5162.

19. Terada, M., Epner, E., Nudel, U., Salmon, J., Fibach, E., Rifkind, R.A., and Marks, P.A. (1978) Proc. Natl. Acad. Bci. (USA) 75: 2795-2799.

20. Morin, M.J. and Sartorelli, A.C. (1984) Cancer Res.
44: 2807-2812 21. Schwartz, E.L., Brown, H.J., Ni:erenberg, M., Marsh, J.C., and Sartorelli, A.C. (1983) dancer Res. 43:
2725-2730.

22. Sugano, H., Furusawa, M., Kawaguchi, T.; and Ikawa, Y. (1973) ~ibl. Hematol. 39: 943-954.

WO 95/31977 . PGT/US95/06554 -eo-23. Ebert, P.S., Wars, I., and Buell, D.N. (1976; Cancer Res. 36: 1809-1813.

24. Hayashi, M., Okabe, J., and Hozumi, M. (1979; Gann 70: 235-238.

25. Fibach, E., Reuben, R.C., Rifkind, R.A., and Marks, P.A.~(1977) Cancer Res. 37: 440-444.

26. Melloni, E., Pontremoli, S., Damiani, G., Viotti, P., Weich, N., Rifkind, R.A., and Marks, P.A. (1988) Proc. Natl. Acad. Sci. (USA) 85: 3835-3839.
2?. Reuben, R., Khanna, P.L., Gazitt, Y., Breslow, R., Rifkind, R.A., and Marks, P.A. (1978) J. Biol. Chem.
253: 4214-4218.
28. Marks, P.A. and Rifkind, R.A. (1988) Lnternational Journal of Cell Cloning 6: 230-240.
29. Melloni, E., Pontremoli, S., Michetti, M., Saceo, 0., Cakiroglu, A.G., Jackson, J.F.,. Rifkind, R.A., and Marks, P.A. (1987) Proc Natl Ac~,~ad Sciences (USA) 84: 5282-5286.
30. Marks, P.A. and Rifkind, R.A. (1984) Cancer 54:
2766-2769.
31. Egorin, M.J., Sigman, L.M. VanEcho, D.A., Forrest, A., Whitacre, M.Y., and Aisner, J. (1987) Cancer Res. 47: 617-623.
32. Rowinsky, E.W., Ettinger, D.S., Grochow, L.H., Brundrett, R.B., Cates, A.E., and Donehower, R.C.
(1986) J. Clin. Oncol. 4: 1835-1844.

33. Rowinsky, E.L. Et~irlc.,j~?~', D.S., McGuire, W.P., N~ve, D.A., Grochow, L.B., and Donehower, R.C. ~i787' Cancer Res. 47: 5788-5795.
34. Gallery, P.S., Egorin, M.J., GeAlhaar, L.A., a:~d ~Nayer, M.S.B..(1986) Cancer Res~. 46: 4900-4903.
35. Young, C.W. Fanucchi, M.P., Walsh, T.B., Blatzer, L., ~Yaldaie, S., Stevens, Y.W., Gordon, C., Tong, W., Rifkind, R.A., and Marks, P.A. (1988) Cancer Res. 48: 7304-7309. .
36. Andreeff, M., Young, C., Clarkson, H., Fetten, J., 'Rifkind, R.A., and Marks, P.A. (1988) Blood 72:
186a.
37. Marks, P.A., Breslow, R., Rifkind, R.A., Ng'o, L., and Singh, R. (1989) Proc. Natl. Acad. Sci. (USA) 86: 6358-6362.
38. Hreslow, R., Jursic, B., Yan, Z.F., Friedman, E., Leng, L., Ngo, L., Rifkind, R.A., and Marks, P.A.
(1991) Proc; Natl: Acad. Sci. (USA), 88: 5542-5546.
39. Ohta, Y., Tanaka, M., Terada, M:, Miller, O.J'., Bank, A., MarkS,~P.A., and Rifkind, R.A. (1976) Proc. Natl. Acad. Sci: (USA) 73: 1232-1236.-40. Collies, S.J., Gallo, R.C., and Gallagher, R.E.
(I978) Nature (London) 2?0; 405-409.
41. Syr~der, S.W., Egorin, M.J., Geelhaar, L.A., Haarburger, A.W., and Gallery, P.S. (1988) n r Res. 48; 3613-3616.

Claims

1. A compound having the structure:
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, aryloxy, carbonylhydroxylamino, or fluoro group;
and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8; or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1, wherein each of X and Y is a hydroxylamino group; R1 is a methyl group; R2 is a hydrogen atom; and each of m and n is 2.

3. A compound of claim 1, wherein each of X and Y is a hydroxylamino group; R1 is a carbonylhydroxylamino group; R2 is a hydrogen atom; and each of m and n is 5.

4. A compound of claim 1, wherein each of X and Y is a hydroxylamino group; each of R1 and R2 is a fluoro group; and each of m and n is 2.

5. A compound having the structure:
wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; or a pharmaceutically acceptable salt thereof.

6. A compound of claim 5, wherein R1 is a phenylamino group and R2 is a hydroxylamino group.